OBJECTIVE/ BACKGROUND: While cognitive-behavioral therapy for insomnia (CBT-I) has been shown to be efficacious in treating cancer survivors' insomnia, 30-60% of individuals have difficulty adhering to intervention components. Psychosocial predictors of adherence and response to CBT-I, such as social support, have not been examined in intervention studies for cancer survivors. PARTICIPANTS: Data from a randomized placebo-controlled 2 x 2 trial of CBT-I and armodafinil (a wakefulness promoting agent) were used to assess adherence. Ninety-six cancer survivors participated in the trial (mean age 56, 86% female, 68% breast cancer). METHODS:CBT-I and armodafinil were administered over the course of seven weeks, and participants were assessed at baseline, during intervention, postintervention, and at a three-month follow-up. Social support was assessed using a Functional Assessment of Chronic Illness Therapy subscale, insomnia severity was assessed using the Insomnia Severity Index, and adherence was measured based on CBT-I sleep prescriptions. RESULTS: At baseline, social support was negatively correlated with insomnia severity (r = -0.30, p = 0.002) and associations between social support, CBT-I, and insomnia were maintained through the three-month follow-up. Social support was positively associated with adherence to CBT-I during intervention weeks 3, 4, and 5, and with overall intervention adherence. At postintervention, both social support and treatment with CBT-I independently predicted decreased insomnia severity (p < 0.01) when controlling for baseline insomnia severity. CONCLUSIONS: Higher social support is associated with better intervention adherence and improved sleep independent of CBT-I. Additional research is needed to determine whether social support can be leveraged to improve adherence and response to CBT-I.
RCT Entities:
OBJECTIVE/ BACKGROUND: While cognitive-behavioral therapy for insomnia (CBT-I) has been shown to be efficacious in treating cancer survivors' insomnia, 30-60% of individuals have difficulty adhering to intervention components. Psychosocial predictors of adherence and response to CBT-I, such as social support, have not been examined in intervention studies for cancer survivors. PARTICIPANTS: Data from a randomized placebo-controlled 2 x 2 trial of CBT-I and armodafinil (a wakefulness promoting agent) were used to assess adherence. Ninety-six cancer survivors participated in the trial (mean age 56, 86% female, 68% breast cancer). METHODS:CBT-I and armodafinil were administered over the course of seven weeks, and participants were assessed at baseline, during intervention, postintervention, and at a three-month follow-up. Social support was assessed using a Functional Assessment of Chronic Illness Therapy subscale, insomnia severity was assessed using the Insomnia Severity Index, and adherence was measured based on CBT-I sleep prescriptions. RESULTS: At baseline, social support was negatively correlated with insomnia severity (r = -0.30, p = 0.002) and associations between social support, CBT-I, and insomnia were maintained through the three-month follow-up. Social support was positively associated with adherence to CBT-I during intervention weeks 3, 4, and 5, and with overall intervention adherence. At postintervention, both social support and treatment with CBT-I independently predicted decreased insomnia severity (p < 0.01) when controlling for baseline insomnia severity. CONCLUSIONS: Higher social support is associated with better intervention adherence and improved sleep independent of CBT-I. Additional research is needed to determine whether social support can be leveraged to improve adherence and response to CBT-I.
Authors: Ann M Berger; Jean L Grem; Constance Visovsky; Heather A Marunda; Justin M Yurkovich Journal: Oncol Nurs Forum Date: 2010-11 Impact factor: 2.172
Authors: Arianna Aldridge-Gerry; Jamie M Zeitzer; Oxana G Palesh; Booil Jo; Bita Nouriani; Eric Neri; David Spiegel Journal: Sleep Med Date: 2013-09-05 Impact factor: 3.492
Authors: David Spiegel; Lisa D Butler; Janine Giese-Davis; Cheryl Koopman; Elaine Miller; Sue DiMiceli; Catherine C Classen; Patricia Fobair; Robert W Carlson; Helena C Kraemer Journal: Cancer Date: 2007-09-01 Impact factor: 6.860
Authors: Kathleen J Yost; Carrie A Thompson; David T Eton; Cristine Allmer; Shawna L Ehlers; Thomas M Habermann; Tait D Shanafelt; Matthew J Maurer; Susan L Slager; Brian K Link; James R Cerhan Journal: Leuk Lymphoma Date: 2012-09-06
Authors: Divya A Parikh; Rani Chudasama; Ankit Agarwal; Alexandar Rand; Muhammad M Qureshi; Taylor Ngo; Ariel E Hirsch Journal: Int J Breast Cancer Date: 2015-10-28
Authors: Anao Zhang; Kaipeng Wang; Kate Blumenstein; Anna Brose; Chris Kemp; Dalton Meister; Phyllis Solomon Journal: Support Care Cancer Date: 2022-08-30 Impact factor: 3.359